At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the immune response from STRIDE, a randomised, phase 2, open-label trial of sipuleucel-T with concurrent versus sequential enzalutamide administration in patients with metastatic castration-resistant prostate cancer.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Advertisement